Boehringer Ingelheim collaborates with MabGenesis to explore potential canine therapeutic treatments
The global pharma concern, Boehringer Ingelheim, on Tuesday, announced that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential canine therapeutic treatments. The former is bringing critical diversity to innovation by utilizing a wealth of different experiences and skills throughout the global community of scientists in both human and animal health.
“We believe that collaboration and shared innovation can lead to groundbreaking solutions to better predict, prevent, detect and treat diseases. This strategic partnership is another example of our commitment to address unmet needs in the animal health market with the aim to improve the lives of animals and humans.”Stephen Martin, Head of Research, Boehringer Ingelheim Animal Health
MabGenesis will use its unique platform to discover first-in-class candidate antibodies against targets of interest chosen by Boehringer Ingelheim under the terms of the agreement. The alliance will grant Boehringer Ingelheim the ability to develop and commercialize products.
“We are excited to partner with global animal health leader Boehringer Ingelheim as we feel we bring complementary expertise to this collaboration. The combination of our innovative discovery platform, MOURA Library and IMPACT, and Boehringer Ingelheim’s capability and industry leadership will surely lead to the discovery of innovative canine therapeutic antibodies bringing benefits to animal health.”Katsuhiro Shinjo, DVM, PhD, Chief Executive Officer of MabGenesis
On the association, the Head of Business Development & Licensing at Boehringer Ingelheim Animal Health, Frerich de Vries said, “Collaborating with innovative and entrepreneurial partners contributes to solving the biggest challenges in animal health. The new areas of science, such as stem cell therapeutics and species-specific monoclonal antibody technology, hold the key to revealing new ways to tackle disease, where limited or no treatment options exist, and provide the opportunity to unlock the next wave of transformational solutions.”